annotations:
  0:
    - object: CHD Death
    - object: Non-fatal MI
    - object: Ischemic Stroke
  1:
    - object: Acute Febrile Illness
  2:
    - object: Alanine Aminotransferase (ALT) Level Elevation
    - object: Aspartate Aminotransferase (AST) Level Elevation
  3:
    - object: Change from Baseline in CD4/CD8 Cell Counts
  4:
    - object: Toxicity
  5:
    - object: Costs for Referrals to Radiography
  6:
    - object: Duration of Solicited Local Symptoms
  7:
    - object: Partial Onset Seizures (Type I)
  8:
    - object: Change in Leibowitz Social Anxiety Scale (LSAS) Total Score
  9:
    - object: Area Under the Plasma Concentration-time Curve
  10:
    - object: Transitional Dyspnea Index (TDI) Score
  11:
    - object: Progression-free Survival
  12:
    - object: Equivalence of Seroprotection Against Poliovirus
  13:
    - object: Change from Baseline in Vital Sign Parameter of Heart Rate
  14:
    - object: Brief Psychiatric Rating Scale
  15:
    - object: Change in Anxiety Symptoms
  16:
    - object: Lipids
  17:
    - object: Invasive Ventilator-Free Survival
  18:
    - object: Inflammatory Bowel Disease Questionnaire (IBDQ) Social Function Domain Score
  19:
    - object: Transplants in Which Participants Achieved Platelet (PLT) Engraftment
  20:
    - object: Change from Baseline in Subjective Sleep Onset Latency
  21:
    - object: Operator Satisfaction
  22:
    - object: Trough FEV1 Response
  23:
    - object: Change from Baseline in Blood Eosinophils (Cells/uL)
  24:
    - object: Most Frequent Grade 3-4 Hematology Abnormalities
  25:
    - object: Maximum Plasma Concentration
  26:
    - object: Change in Diabetes
  27:
    - object: Serum Iron
  28:
    - object: Change from Baseline in Number of Glucose-Lowering Treatments
  29:
    - object: Occurrence of Treatment-emergent Adverse Events
    - object: Severity of Treatment-emergent Adverse Events
  30:
    - object: Best Overall Response Rate
  31:
    - object: Difference in Pediatric Evaluation of Disability Inventory (PEDI) Functional Skills Scores
  32:
    - object: Clinical Global Impression Improvement Score
  33:
    - object: Descend Steps Pre-Intervention
  34:
    - object: Maximum Severity
  35:
    - object: At Least 10mm Difference in VAS Pain Scale Scores
  36:
    - object: Change in Adinopectin
  37:
    - object: Change from Baseline in HAQ-DI
  38:
    - object: Adverse Events
  39:
    - object: 20% Improvement (ACR20)
  40:
    - object: TEAEs
    - object: Grade >= 3 TEAEs
    - object: Serious TEAEs
    - object: Treatment Related TEAEs
  41:
    - object: Buccal Cells Demonstrating a Decline in Cyclin D1
  42:
    - object: Maximum Total Daily Number of Self-Reported Spray Doses
  43:
    - object: Change in Infant Sleep Quantity
  44:
    - object: Change in Emotional Well-Being (EWB) Subscale Score
  45:
    - object: Adverse Events
  46:
    - object: PIK3CA Mutation at Baseline
  47:
    - object: eSAGE Score Compared to Hopkins Verbal Learning Test (HVLT) Score
  48:
    - object: Visual Analog Pain Scale
  49:
    - object: Clinical Global Impressions of Severity (CGI-S) Total Score
  50:
    - object: Patient Satisfaction
  51:
    - object: Corneal Staining Score
  52:
    - object: â‰¥4-fold Rise for Anti-H2 Full Length HA ELISA Antibody Concentration
  53:
    - object: Change in Elvitegravir (EVG) Concentration
  54:
    - object: Change in PTSD Symptoms
  55:
    - object: Cases of Non-Serotype Specific Dengue Viremia
  56:
    - object: Grade 3-4 Immune Mediated Adverse Events (IMAEs)
  57:
    - object: Correlation Between Change in Pain Intensity and TBW
  58:
    - object: Area Under the Plasma Concentration-time Curve Versus Time Curve 
  59:
    - object: Change From Baseline in MSIS-29 Psychological Score
  60:
    - object: Implant Insertion Time
  61:
    - object: Confirmed Best Objective Response
  62:
    - object: Treatment-emergent Resistance-associated Substitutions to OBT Components
  63:
    - object: Change From Baseline in Exercise Tolerance
  64:
    - object: Associations Between Polymorphisms
    - object: Efficacy
    - object: Toxicities
  65:
    - object: Response Rate
  66:
    - object: Area Under Curve
  67:
    - object: Heartburn-Free 24-hour Days
  68:
    - object: Change From Baseline in Triiodothyronine (T3)
  69:
    - object: Worst Case Body Temperature Values of PCI
  70:
    - object: Systolic Blood Pressure <90 mmHg 
  71:
    - object: Any Abnormal Glycosylated Hemoglobin (HbA1c) Value
  72:
    - object: Concentration of REGN10933
  73:
    - object: Surgical Site Occurrence Rate
  74:
    - object: Rate of Decline in Forced Vital Capacity (FVC)
  75:
    - object: Maternal Morbidity
  76:
    - object: CD22 Expression Levels 
  77:
    - object: Change in Basophils
  78:
    - object: Rescue Medication
  79:
    - object: Pathogen Identified 
  80:
    - object: Time to Need for Antibiotics for Respiratory Event
  81:
    - object: Incidence of Cervical Intraepithelial Neoplasia
  82:
    - object: Change in SBP from Baseline
  83:
    - object: Safety
  84:
    - object: Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)
  85:
    - object: Hot Flash Related Daily Interference Scale (HFRDIS)
  86:
    - object: Change From Baseline in Mean Worse Eye Intraocular Pressure
  87:
    - object: Change From Baseline in Cartilage Thickness of the Total Tibiofemoral Compartment (tTFC)
  88:
    - object: Change From Baseline in Brief Fatigue Inventory (BFI) Worst Fatigue Score
  89:
    - object: AUC
  90:
    - object: Recurrent Disease
  91:
    - object: Progression-free Survival
  92:
    - object: Health Assessment Questionnaire-Disability Index Changes
  93:
    - object: Snack Added Sugars Purchased
  94:
    - object: Overall Survival
  95:
    - object: Change From Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Sub-score for Pain
    - object: Change From Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Sub-score for Activities of Daily Living (ADL)
  96:
    - object: Magnitude of Suppression of Plasma Renin Activity
  97:
    - object: Terminal Half-life
  98:
    - object: Eyelids With Each of the Trichiasis Severity Levels
  99:
    - object: Retrospective-Modified Overt Aggression Scale (R-MOAS) Remission Rate
  100:
    - object: adverse effects